Spots Global Cancer Trial Database for Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
Official Title: Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial
Study ID: NCT02555800
Conditions
Study Description
Brief Summary: The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.
Detailed Description: The investigators designed a randomized, double-blind, placebo-controlled study. Children and adults will be randomized to receive either 3 dosis of intralesional bevacizumab, cidofovir or saline solution. Primary endpoints are the assessment of changes in the annual surgery rate and Derkay papilloma severity grading scale; secondary endpoints are changes in the Voice Handicap Index and safety.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centro de Investigacion en Enfermedades Infecciosas, Mexico, , Mexico
Contact Details
Name: Gustavo Reyes-Terán, M.D.
Affiliation: Centro de Investigación en. Enfermedades Infecciosas, Mexico
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
